Mavacamten improves functional capacity and symptoms in adults with New York Heart Association class II-III obstructive HCM.
Aleksandra Bieniek, PharmD
Advertisement
Articles by Aleksandra Bieniek, PharmD
Advertisement
Latest Updated Articles
First-in-Class Treatment for Obstructive Hypertrophic Cardiomyopathy Is Approved by FDAPublished: October 11th 2022 | Updated:
Advertisement
Advertisement
Trending on Drug Topics
1
Lower Baseline BMI Predicts Weight Loss At 6 Months With Liraglutide
2
Providers, Patients Show Favorable Perception of Remdesivir During COVID-19 Pandemic
3
PCV21 Shows Cost Effectiveness Compared With PCV15, PCV13, and PPSV23
4
How the Delinking Model Can Drive Transparency, Avoid PBM Manipulation | NCPA 2025
5
